Overview

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study was conducted to provide detailed information on the efficacy of indacaterol (in terms of the spirometry assessment forced expiratory volume in 1 second [FEV1]) over the full 24-h time period
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Salmeterol Xinafoate